Testing effectiveness (Phase 2)UnknownNCT03534635
What this trial is testing
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
Who this might be right for
Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting
Centre Hospitalier Universitaire Vaudois 30